FILGRASTRIM (G-CSF; granulocyte-colony stimulating factor)

Therapeutic class: Colony stimulating factor Pharmacologic class: Hematopoietic Use\ Indications Congenital neutropenia, Idiopathic or cyclic neutropenia, Peripheral blood progenitor cell collection and therapy in cancer patients, Febrile Neutropenia, to decrease risk of infection in patients with nonmyeloid malignant disease receiving myelosuppressive antineoplastics, bone marrow transplantation Pharmacological Effects The myeloid growth factors stimulate proliferation and differentiation by interacting with specific receptors found on various myeloid progenitor cells. It also activates the phagocytic activity of mature neutrophils and prolongs their survival in the circulation. G-CSF also has a remarkable ability to mobilize hematopoietic stem cells, i.e., to increase their concentration in peripheral blood. Adverse Reactions CNS: fever, headache, weakness, fatigue. CV: MI, arrhythmias, chest pain, hypotension. GI: nausea, vomiting, diarrhea, mucositis, stomatitis, constipation. Hematologic: thrombocytopenia, leukocytosis, NEUTROPENIC FEVER. Metabolic: hyperuricemia. Musculoskeletal: bone pain. Respiratory: dyspnea, cough. Skin: alopecia, rash, cutaneous vasculitis. Other: hypersensitivity reactions. Pregnancy: C Breast-feeding: Use cautiously Precautions/Warnings/Contraindication severe congenital neutropenia (Kostmanns syndrome) with abnormal cytogenetics Interactions: Amphotericin B, cephalosporins, clindamycin, dactinomycin, etoposide, fluorouracil, furosemide, heparin sodium, mannitol, ethylprednisolone sodium succinate, metronidazole, mitomycin, piperacillin, prochlorperazine edisylate, sodium solutions, thiotepa. Dosing 5-10 mcg/kg daily, I.V. infusion of 4 or 24 hours or as continuous 24-hour subcutaneous infusion, at least 24 hours after cytotoxic chemotherapy and bone marrow infusion. Brand Names Parentrals: Neupogen-300mcg